Synageva BioPharma
Corporate Offices
128 Spring Street, Suite 520
Lexington
Massachusetts
02421
United States
Tel: 781-890-1111
Fax: 781-890-1114
Website: http://www.synageva.com/
Email: info@synageva.com
About Synageva BioPharma
Synageva BioPharma is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need. Our lead program, SBC-102, an enzyme replacement therapy for LAL Deficiency, is currently being evaluated in global Phase I/II clinical trials. SBC-102 has been granted orphan designations by the U.S. Food and Drug Administration (“FDA”) and the European Medicines Agency and fast track designation by the FDA. Synageva has several protein therapeutics focused on life threatening conditions in its pipeline. The Company has assembled a team with a proven record of bringing orphan therapies to patients.127 articles about Synageva BioPharma
-
Synageva BioPharma Announces Completion of $45 Million Financing with New $12 Million Investment, Addition of New Leaf Venture Partners to Investor Group, and Expansion of Senior Leadership Team
10/20/2009
-
Morphotek Inc. Announces a Research Collaboration Agreement with Synageva BioPharma to Develop Potential Treatments for Cancer and Infectious Disease
7/1/2009
-
Synageva BioPharma Adds $3 Million
5/6/2009
-
Synageva BioPharma Adds Two New Investors and Announces Additional Funding
5/5/2009
-
Synageva BioPharma Announces $30 Million Equity Financing
4/15/2009
-
Synageva BioPharma Appoints Leading Clinician And Industry Executive, Dr. Mark Goldberg, To Its Board of Directors
10/10/2008
-
Synageva BioPharma Appoints Sanj K. Patel President and Chief Executive Officer and Opens New Corporate Headquarters
9/4/2008